Patents by Inventor David Ennist

David Ennist has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of achieving persistent Transgene expression
    Publication number: 20090069257
    Abstract: Non-inflammatory vector compositions are provided that are suitable for repeated transgene delivery and that result in persistent transgene expression. The compositions are non-inflammatory, the present compositions are suitable for readministration and do not induce expression-limiting immune or inflammatory responses. Thus, these compositions are useful in methods of repeated administration to achieve persistent transgene expression, and are especially suited to treating genetic, acquired and inflammation-associated conditions.
    Type: Application
    Filed: April 2, 2007
    Publication date: March 12, 2009
    Inventors: David Ennist, Patrick Lu, Mervat Mina
  • Oncolytic adenoviral vectors encoding GM-CSF
    Publication number: 20080118470
    Abstract: Selectively replicating oncolytic adenoviral vectors comprising an adenoviral packaging signal, a termination signal sequence, an E2F responsive promoter operably linked to an adenoviral coding region, a heterologous coding sequence encoding GM-CSF and a right ITR are provided. The oncolytic adenoviral vectors are useful for expressing GM-CSF in transduced cells and in methods for selectively killing neoplastic cells.
    Type: Application
    Filed: November 5, 2007
    Publication date: May 22, 2008
    Applicant: Cell Genesys, Inc.
    Inventor: David Ennist
  • Oncolytic adenoviral vectors encoding GM-CSF
    Publication number: 20050282280
    Abstract: Selectively replicating oncolytic adenoviral vectors comprising an adenoviral packaging signal a termination signal sequence, an E2F responsive promoter operably linked to an adenoviral coding region, a heterologous coding sequence encoding GM-CSF and a right ITR are provided. The oncolytic adenoviral vectors are useful for expressing GM-CSF in transduced cells and in methods for selectively killing neoplastic cells.
    Type: Application
    Filed: February 28, 2005
    Publication date: December 22, 2005
    Inventor: David Ennist
  • Oncolytic adenoviral vectors encoding GM-CSF
    Publication number: 20050186178
    Abstract: Selectively replicating oncolytic adenoviral vectors comprising an adenoviral packaging signal, a termination signal sequence, an E2F responsive promoter operably linked to an adenoviral coding region, a heterologous coding sequence encoding GM-CSF and a right ITR are provided. The oncolytic adenoviral vectors are useful for expressing GM-CSF in transduced cells and in methods for selectively killing neoplastic cells.
    Type: Application
    Filed: August 23, 2004
    Publication date: August 25, 2005
    Inventor: David Ennist
  • Method of achieving persistent transgene expression
    Publication number: 20030148975
    Abstract: Non-inflammatory vector compositions are provided that are suitable for repeated transgene delivery and that result in persistent transgene expression. The compositions are non-inflammatory, the present compositions are suitable for readministration and do not induce expression-limiting immune or inflammatory responses. Thus, these compositions are useful in methods of repeated administration to achieve persistent transgene expression, and are especially suited to treating genetic, acquired and inflammation-associated conditions.
    Type: Application
    Filed: October 23, 2002
    Publication date: August 7, 2003
    Inventors: David Ennist, Patrick Lu, Mervat Mina